In immune and infection mediated vasculitides, intravascular activation of peripheral blood phagocytes can cause these cells to release highly reactive oxygen metabolites and powerful enzymes. Although phagocytes normally reserve these weapons for destroying invading microorganisms, the pathological activation of neutrophils or monocytes will result in tissue injury and destruction. Phagocytes triggered within the blood vessel lumen have the potential to attack the endothelial cell lining and the underlying basement membrane. Damage to either of these structures can lead to altered vascular permeability, thrombosis, renal or pulmonary dysfunction and possibly atherosclerosis. In this study we will examine the ability of human phagocytes (neutrophils and monocytes) triggered with stimuli likely to be encountered in pathological states (immune complexes, tissue directed antibodies, activated complement components, bacterial peptides) to damage monolayers of cultured, human endothelial cells. In vitro model systems will be constructed to mimic in vivo pathological states with specific emphasis placed on 1) assessing the potential of the triggered phagocytes to damage either the endothelial cell or its underlying basement membrane, 2) characterizing the relative role of oxygen metabolites and neutral proteinases in mediating these injuries and, 3) identifying the final mediators of endothelial cell damage and basement membrane degradation. An understanding of the phagocyte-endothelial cell-basement membrane interaction will not only provide specific information into the pathogenesis of immune-mediated vascular injury but will also provide new insights into the biochemistry of the inflammatory process. Utilizing this information, rational therapeutic interventions can be designed that could attenuate inflammatory damage in a wide range of pathological states.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL028024-08
Application #
3339449
Study Section
Pathology A Study Section (PTHA)
Project Start
1982-01-01
Project End
1993-12-31
Budget Start
1989-01-01
Budget End
1989-12-31
Support Year
8
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Reddy, V Y; Desorchers, P E; Pizzo, S V et al. (1994) Oxidative dissociation of human alpha 2-macroglobulin tetramers into dysfunctional dimers. J Biol Chem 269:4683-91
Mulligan, M S; Desrochers, P E; Chinnaiyan, A M et al. (1993) In vivo suppression of immune complex-induced alveolitis by secretory leukoproteinase inhibitor and tissue inhibitor of metalloproteinases 2. Proc Natl Acad Sci U S A 90:11523-7
Desrochers, P E; Mookhtiar, K; Van Wart, H E et al. (1992) Proteolytic inactivation of alpha 1-proteinase inhibitor and alpha 1-antichymotrypsin by oxidatively activated human neutrophil metalloproteinases. J Biol Chem 267:5005-12
Huber, A R; Kunkel, S L; Todd 3rd, R F et al. (1991) Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science 254:99-102
Desrochers, P E; Jeffrey, J J; Weiss, S J (1991) Interstitial collagenase (matrix metalloproteinase-1) expresses serpinase activity. J Clin Invest 87:2258-65
Rice, W G; Weiss, S J (1990) Regulation of proteolysis at the neutrophil-substrate interface by secretory leukoprotease inhibitor. Science 249:178-81
Huber, A R; Weiss, S J (1989) Disruption of the subendothelial basement membrane during neutrophil diapedesis in an in vitro construct of a blood vessel wall. J Clin Invest 83:1122-36
Weiss, S J (1989) Tissue destruction by neutrophils. N Engl J Med 320:365-76
Desrochers, P E; Weiss, S J (1988) Proteolytic inactivation of alpha-1-proteinase inhibitor by a neutrophil metalloproteinase. J Clin Invest 81:1646-50
Trochelman, R D; Weiss, S J; Regiani, S et al. (1988) Expression of Mo3e antigen by cultured human umbilical vein endothelial cells (HUVEC) stimulated by phorbol myristate acetate (PMA) and related pharmacological inducers of protein kinase C. Cell Immunol 112:89-103

Showing the most recent 10 out of 14 publications